Combination of Ashwagandha Water Extract and Intermittent Fasting as a Therapy to Overcome Cisplatin Resistance in Breast Cancer: An in vitro and in vivo Study

Sajidah Jawarneh and Wamidh H. Talib*

Department of Clinical Pharmacy and Therapeutics, Applied Science Private University, Amman, Jordan

Breast cancer is considered a universal public health dilemma in women. Due to the high toxicity and low selectivity of conventional anticancer therapies, there is a growing trend of using plant-derived natural products in cancer prevention and therapy. Ashwagandha (Withania somnifera, WS) has been used in the Mediterranean region and Ayurvedic medicine for millennia as a functional food and a medicinal plant with anticancer activity. Besides, intermittent fasting (IF) has been engaged recently in cancer treatment. Hence, the combination of WS and IF provides possible solutions to treat cancer and reduce chemoresistance when combined with chemotherapy. In this study, WS root (WSR), IF, and cisplatin were tested on cisplatin-sensitive (EMT6/P) and cisplatin-resistant (EMT6/CPR) mouse mammary cell lines. The phytochemical content of the WSR extract was analyzed using liquid chromatography–mass spectrometry (LC-MS) analysis. Antiproliferative and apoptotic effects were assessed for WSR extract, cisplatin, and their combination in vitro using [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] (MTT) and caspase-3 assays. An in vivo study was used to assess the effect of WSR extract, IF, cisplatin, and their combinations in mice inoculated with EMT6/P and EMT6/CPR cells. The safety profile was also investigated using liver enzymes and creatinine assays. In vitro, WSR extract and cisplatin had a synergistic effect in both cell lines. The same combination induced an apoptotic effect higher than the single treatment in both cell lines. In vivo, several combinations of WSR extract, IF, or cisplatin caused significant tumor size reduction and improved the cure rate in mice implanted with EMT6/P and EMT6/CPR cell lines. IF-treated groups showed a significant reduction in serum glucose and an elevation in β-hydroxybutyrate (BHB) levels. In the safety profile, WSR extract, IF, and their combinations were safe. Overall, the combination of WSR extract and IF provides a promising solution for breast cancer treatment besides cisplatin by reducing the proliferation of cancer cells through induction of apoptosis. Moreover, they minimize cisplatin toxicity to the liver and kidney.

Keywords: breast cancer, nutritional intervention, Ashwagandha, intermittent fasting, multidrug resistance, cisplatin, apoptosis, Warburg effect
INTRODUCTION

Breast cancer is a major public health problem because it is the second cause of death and the most common cancer in women worldwide. Resistance to cancer treatments plays a major role in breast cancer issue exacerbation (1). As an example, cisplatin is uniformly used in cancer treatment; nevertheless, its use is limited because of serious side effects and resistance (2). Resistance is divided into primary drug resistance and multidrug resistance (MDR) (3). To clarify, MDR is the resistance of cancerous cells to various anticancer drugs with different structures and mechanisms of action. Chemoresistance has several molecular mechanisms, such as deregulation of apoptosis, deregulated autophagy, enhanced DNA damage repair, and p53 inactivation (4).

Apoptosis is the natural mechanism for programmed cell death. Apoptosis has two major pathways: extrinsic and intrinsic. In the extrinsic pathway, the death legends (e.g., TNF and Fas-L) activate the formation of a death-inducing signaling complex (DISC). This results in the formation of caspase-8 and –10 followed by executioner caspases-3, –6, and –7 activation (5). In the intrinsic pathway, different apoptotic stimuli upregulate BCL-2 homology domain 3 (BH3)-only proteins, which activate BCL-2 homology domain 3 (BH3) and BCL-2 homology domain 3 (BH3), releasing cytochrome-c. Then, cytochrome-c facilitates the conversion of procaspase-9 to caspase-9, which can activate the executioner caspases-3 and –7. The latter start to hold up proteins leading to cell death (6). Therefore, overexpression of oncogenes mediates the inhibition of apoptosis and that leads to the suppression of p53, enhancement of antiapoptotic proteins, such as B cell CLL/lymphoma-2 (Bcl-2), and downregulation of pro-apoptotic proteins like caspases, Bcl-XL/Bcl-2-associated death promoter (Bad), and BAX/BAK. Therefore, several researchers have targeted caspases to overcome resistance to chemotherapy (5).

Nutrition interventions have valuable effects in terms of cancer prevention and treatment (7). For example, Ashwagandha has been used as an indispensable plant in the Mediterranean region and in Ayurvedic medicine for millennia (8) as a functional food due to its immense nutritional value with various biological effects like cancer (9). Comparatively, intermittent fasting (IF) has been engaged in the newly developing treatment approaches because of its benefit in fighting cancer (10).

Ashwagandha (Withania somnifera, WS) belongs to the family Solanaceae and has been used as an antitumor, anti-inflammatory, anti-diabetic, anti-stress, hepatoprotective, and nephroprotective agent (11). WS root (WSR) has many active constituents, such as alkaloids, flavonoids, withanolides (e.g., withaferin A and withanine), and succinic acid (11, 12). WSR extract can promote apoptosis in breast cancer through caspase-3 activation and downregulation of the antiapoptotic protein Bcl-2 (13). Additionally, it enhances the efficacy of both chemotherapy and radiotherapy (14).
There is growing attention to harnessing IF to minimize tumor growth and improve cancer treatment efficacy. IF mimics Ramadan fasting in Islamic countries, which is applied in many of the Mediterranean region’s countries (15). It reduces glucose levels and affects glucose metabolism (glycolysis) inside the cell by reversing the Warburg effect (16). IF depends on calorie restriction or fasting over an extended period (e.g., 16–48 h). This time is enough to activate ketogenesis increasing ketones [e.g., β-hydroxybutyrate (BHB) and acetoacetate], mitochondrial stress resistance, antioxidant defense, and autophagy (17). Currently, IF is used as an adjunct therapy for cancer along with chemotherapy. When used for short terms, it enhanced the chemotherapeutic effect. Moreover, short terms use of fasting showed elevation in oxidative stress and DNA damage causing induction of apoptosis (10).

In this perspective, the Warburg effect (aerobic glycolysis) represents an essential hallmark of cancer, since cancer cells have accelerated glycolysis and exaggerated lactate production, even under fully oxygenated conditions. This ends with oxidative stress reduction and consequently, resistance to diverse factors including apoptosis and cytotoxic drugs. In the bargain, lactate production produces an acidic environment, which is compatible with proliferation and metastasis (18).

A combination of herbal extract with fasting and a triple combination of herbal extract, fasting, and chemotherapy has not been evaluated in the literature to treat cancer. Accordingly, this study was designed to test the effect of WSR extract with IF with cisplatin as a new combination therapy to overcome cisplatin-resistant breast cancer in a mouse model.

MATERIALS AND METHODS

Extract Preparation
Powdered WSR was purchased from Zokiva Nutritionals, US. The extract preparation was performed following the protocol previously optimized by Kumar et al. (19). Briefly, 5 gm of the powdered root was infused in 250 ml (1:50 w/v) of freshly boiled double distilled water (DDW) for 25 min. After that, the infusion was left to cool to room temperature and centrifuged (12,000 rpm or 8050 X g, 15 min). The supernatants were recentrifuged (12,000 rpm, 10 min) (19). The supernatants were then dried in the oven at 50°C (20). The yield of the dried aqueous extract was 1.4 g (Figure 1).

Liquid Chromatography–Mass Spectrometry Analysis
The preparation of the sample was carried out by dissolving 20 mg of WSR extract in 2 ml DDW and then completed with acetonitrile to 50 ml. The sample was centrifuged at 4,000 rpm for 2 min. The autosampler was then loaded with 1 ml of the sample and the injection volume was 3 µl. The instrument was utilized by Ion Source Apollo II ion funnel electrospray source with the following characteristics [dry gas flow 8 l/min; capillary voltage: 2500 v; nebulizer gas: 2 bar; dry temperature: 200°C; mass accuracy: < 1 ppm; mass resolution: 50,000 FRS (Full Sensitivity Resolution); the time-of-flight (TOF) repetition rate: up to 20 kHz]. The separation was accomplished via a Burker solo 2-C-18 ultra-high performance liquid chromatography (UHPLC) column (100 mm × 2.1 mm × 2 µm) at a flow rate of 0.51 ml/min and a column temperature of 40°C. All standards were used for the identification of m/z and the retention time. The analysis was performed by Burker Daltonik (Bremen, Germany) impact II ESI-Q-TOF system provided with Burker Dalotonik Elute UPLC system (Bremen, Germany) used for screening compounds of interest.

In vitro Experiments
Cell Lines and Culture Conditions
Two mouse mammary cell lines were used in this study: the parent (EMT6/P) and cisplatin resistance (EMT6/CPR) cell lines...
were purchased from the European Collection of Authenticated Cell Cultures (ECACC; Salisbury, United Kingdom). Cells were grown in minimal essential medium (MEM) supplemented with 10% fetal bovine serum, 1% L-glutamine, 0.1% gentamicin, 1% penicillin-streptomycin solution, and 0.1% non-essential amino acids. Perfect cell culture conditions were provided for cell growth using complete tissue culture media (MEM). All cell lines were incubated in a carbon dioxide (CO2) incubator at 37°C using complete tissue culture media (MEM). All cell lines were exposed to different concentrations of WSR extract with different light/dark cycles of 12 h.

**Antiproliferative Assay (MTT)**

The antiproliferative activity was detected using MTT (the tetrazolium salt, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; Sigma, Saint Lucia, United States). The mouse mammary cell lines (EMT6/P and EMT6/CPR) were cultured overnight. Cells were collected using the trypsinization technique, and the exponentially growing cells were counted using the trypan blue exclusion method. After that, the cells were seeded at 10,000 cells/well in 96-well tissue culture flat-bottom microplates for 24 h incubation. After seeding, both the cell lines were exposed to different concentrations of WSR extract (0.39–50 mg/ml) for 48 h. They were also exposed to cisplatin (0.8–100 μM) for 48 h.

In combination treatment, EMT6/P cells were exposed to increasing concentrations of WSR extract (0.01–1.5 mg/ml) with a fixed dose of cisplatin (10 μM) in EMT6/P. In the resistant cell line, cells were exposed to the extract with different concentrations (0.02–2 mg/ml), with a fixed concentration of cisplatin (27 μM). The reduced MTT assay was assayed at 550 nm using a microplate reader (Biotek, Winooski, VT, United States). Percentage cell survival was calculated for all treatments and compared with untreated cells.

The combination index (CI) was calculated for the WSR extract and cisplatin combination using the previous equation (21), and the resistance fold (RF) was calculated using the following formula (22):

\[
CI = (D_1)/(D_1) + (D_2)/(D_2) + α(D_1)(D_2)/(D_1)(D_2)
\]

Where:

\(D_1\) = The half-maximal inhibitory concentration (IC\(_{50}\)) of WSR extract alone
\(D_2\) = IC\(_{50}\) of WSR extract in combination with cisplatin
\(α\) = 0 for mutually exclusive or 1 for mutually nonexclusive interaction. Depending on the literature review, both WSR extract and cisplatin exert their anticancer effect by different mechanisms of action. Hence, we applied the mutually nonexclusive model, where \(α = 1\).

CI values are explained according to the following:

- CI > 1.3 = antagonism,
- CI = 1.1–1.3 = moderate antagonism,
- CI = 0.9–1.1 = additive effect,
- CI = 0.8–0.9 = slight synergism,
- CI = 0.6–0.8 = moderate synergism,
- CI = 0.4–0.6 = synergism,
- CI = 0.2–0.4 = strong synergism

**Measuring Apoptosis Induction in Cultured Cells**

The caspase-3 assay was used to determine the apoptotic effect of WSR extract and cisplatin in parent and drug resistance cell lines. EMT6/P flasks were treated with IC\(_{50}\) concentrations of WSR extract (2.9 mg/ml), cisplatin (positive control; 20 μM), and combination treatment of the extract and cisplatin (0.54 mg/ml + 10 μM, respectively). EMT6/CPR flasks were treated with IC\(_{50}\) concentrations of the extract (3.8 mg/ml), cisplatin (positive control; 54 μM), and combination treatment of the extract and cisplatin (0.66 mg/ml + 27 μM, respectively). MEM was used as the negative control. The flasks were then incubated for 48 h. After treatment, cells were collected, washed, and lysed using lysis buffer. Caspase-3 activity was measured using the procedure provided in the standard kit (Caspase-3 Assay Kit, My BioSource, United States).

**In vivo Experiments**

**Mice**

Forty-two female Balb/C mice weighing 21–25 g (4–6 weeks old) were used in this study. Mice were supplied by the animal house in the Applied Science Private University, Amman, Jordan. All protocols of animal experiments were validated by the Research and Ethical Committee of Applied Science University with Standard ethical guidelines. The animals were kept in separate cages with bedding of wooden shavings. The provided conditions in the animal house included stable temperature at 25°C, 50–60% humidity, continuous air ventilation, and alternating light/dark cycles of 12 h.

**Tumor Inoculation**

Exponentially growing EMT6/P and EMT6/CPR cells were harvested by trypsinization and were washed and resuspended in MEM, at a density of 1.5 × 10\(^6\) cells/ml. After that, viability was detected using the trypan blue exclusion method. A tumor induction dose of 1.5 × 10\(^5\) cells in 0.1 ml medium was injected into the abdominal area of each female BALB/C mouse subcutaneously and maintained for 14 days to grow and form new tumors.

**Mice Groups, Treatment, and Antitumor Activity**

Each mouse was inoculated with EMT6/P on the right side and EMT6/CPR on the left side. The treatments were started 14 days after tumor inoculation. Forty-two tumor-bearing mice were used in this investigation, and the mice were divided into seven groups (\(N = 6\) for each group; Figure 2A). Group 1 was used as a negative control and was exposed to intraperitoneal injection of the vehicle (phosphate-buffered saline, PBS) of 0.1 ml daily. Group 2 was treated with cisplatin (5 mg/kg/week) by intraperitoneal injections (23). Group 3 was treated with a daily dose of WSR extract (100 mg/kg/d; 24) by gavage. Group 4 was exposed to a daily 18 h of IF and 6 h of
In vivo mice study. (A) Groups of cisplatin-sensitive (EMT6/P) and cisplatin-resistant (EMT6/CPR) inoculated mice. Treatments were: WSR extract (100 mg/kg/d) by gavage, a daily 18 h of intermittent fasting (IF) and 6 h of eating or/and cisplatin (5 mg/kg/week) by intraperitoneal injections for 10 days. (B) Scheme for mice experiment (n = 6).

Tumor dimensions were measured using a digital caliper. The following formula was used to calculate the tumor volumes (22):

\[
\text{Tumor volume} = L \times W^2 \times 0.5
\]

where \(L\) = length of the longest aspect of the tumor,
\(W\) = length of the tumor aspect perpendicular to \(L\).

Finally, mice were killed by cervical dislocation. The tumors were removed, weighed, and stored in 10% formalin to preserve their morphology.

Evaluation of Serum \(\beta\)-Hydroxybutyrate and Serum Glucose Levels

Blood levels of glucose and BHB were assessed on days: 1, 5, and 10, and compared with normal-untreated mice bearing no tumor. Blood glucose levels were measured using the Accu-Chek blood glucose monitoring system (Roche, Basel, Switzerland). BHB Assay Kit (Sigma, United States) was used to measure the levels of BHB in the serum.

Evaluation of Liver and Kidney Function in Treated Mice

The level of toxicity exerted by different treatments on the liver and kidney was assessed. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine were evaluated for WSR extract, IF, cisplatin, and their combinations in addition to the negative control and normal-untreated group. After a serum sample collection, ALT and AST were tested using ALT/GPT kit, AST/GOT kit, and a creatinine assay kit purchased from (BioSystems, Barcelona, Spain).

Statistical Analysis

Statistical analyses were performed using SPSS (Statistical Package for the Social Science, Chicago, IL, United States 25). All values were expressed as mean ± SEM. IC$_{50}$ values were statistically analyzed using nonlinear regression. Statistical significance among the mice groups was determined using a one-way analysis of variance (ANOVA; post hoc test: Tukey). A probability level less than 0.05 ($p < 0.05$) represented a significant difference among groups. In vivo, six mice per group were used and statistics were conducted using $n = 3$ or $n = 6$ in the different tests.

RESULTS

Liquid Chromatography-Mass Spectrometry Analysis of WS Root Water Extract

According to Liquid chromatography-mass spectrometry (LC-MS) analysis, WSR water extract contained succinic acid (68.52%) as a major compound, and other compounds were found in different concentrations, such as anthranilic acid (16.87%), gallic acid (7.52%), chlorogenic acid (2.81%), and 3,5-dimethoxy-4-hydroxy acetophenone (1.29%; Figure 3). The
rest of the compounds were less than 1%, such as vanillic acid, protocatechuic aldehyde, caffeic acid, ferulic acid (trans), apiin, and salicylic acid, rutin, spiraeside, kaempferol, and isorhamnetin (Table 1).

In vitro Results
Antiproliferative Effect of WS Root Extract, Cisplatin, and Their Combination

MTT assay was conducted to evaluate the antiproliferative activity of WSR extract, cisplatin, and their combination on cisplatin-sensitive (EMT6/P) and cisplatin-resistant (EMT6/CPR) cell lines. Single treatment of WSR extract or cisplatin attenuated cell proliferation compared with the vehicle control in a concentration dependent pattern as observed in Figures 4A,B. Our results revealed that EMT6/CPR cells presented higher survival rates compared to EMT6/P cells when exposed to the same concentrations of WSR extract or cisplatin. Additionally, EMT6/P and EMT6/CPR cell lines were treated with different concentrations of WSR extract and a fixed concentration of cisplatin. The results showed that this combination significantly concentration-dependently inhibited cell viability (Figures 4C,D).

The analysis of the CI showed that the combination treatment had a moderate synergistic effect employed on EMT6/P and EMT6/CPR cells (CI = 0.78 and 0.76, respectively; Table 2). The mean IC50 values are reported in Table 2, and the IC50 values of the extract were 2.9 ± 0.18 and 3.8 ± 0.09 mg/ml in EMT6/P and EMT6/CPR, respectively, with an RF of 1.31, which means that EMT6/CPR cells were 1.31 times more resistant to the extract than EMT6/P. Oppositely, IC50 of cisplatin was found to be 20 ± 0.5 µM in the EMT6/P cell line and 54 ± 0.08 µM in the EMT6/CPR cell line, which means that EMT6/CPR cells were 2.7 times more resistant to cisplatin in contrast to EMT6/P cells. Thus, a higher concentration of WSR extract or cisplatin is needed to kill 50% of the EMT6/CPR cell line. On the other hand, in the combination, IC50 was 0.54 ± 0.011 mg/ml WSR extract and 10 µM cisplatin in EMT6/P cells and 0.66 ± 0.05 mg/ml WSR extract with 27 µM cisplatin in EMT6/CPR cells. As observed, EMT6/P cells were more susceptible to the combination at lower doses than EMT6/CPR being a resistant cell line that has mechanisms to resist the applied combination. The RF of the combination (1.22) is lower than the RF of either WSR extract or cisplatin single treatment (1.31 and 2.7, respectively), which indicates that the WSR extract sensitized the resistant cells to cisplatin.
Apoptotic Activity of WS Root Extract, Cisplatin, and Their Combination

Caspase-3 activity was performed using a caspase-3 assay kit to evaluate the apoptotic effect of WSR extract, cisplatin, and their combination in EMT6/P and EMT6/CPR cell lines. Results of the analysis in EMT6/P cells indicated a significant difference between WSR extract, cisplatin, and their combination compared to control (p < 0.05) and between the treatment groups themselves (p < 0.05). The combination exhibited 2.98 folds increase in caspase-3 activity compared to the control (Figure 5A). In contrast, the detected results in EMT6/CPR revealed the existence of a significant difference between WSR extract and its combination with cisplatin compared with the control group. As shown in Figure 5B, WSR extract single treatment achieved 1.39 folds increase in caspase-3 activity compared to the control (p < 0.05). Furthermore, the combination of WSR extract and cisplatin achieved 2.31 folds increase in caspase-3 activity compared to the control group with a significant difference (p < 0.001) compared to the cisplatin-treated group, which showed an insignificant response to cisplatin (p = 0.286).

In vivo Results

Antitumor Effect of WS Root Extract, Intermittent Fasting, Cisplatin, and Their Combinations

Based on the results of the in vitro assay, WSR extract was selected in addition to IF, cisplatin, and their combinations for further evaluation to assess the antitumor activity in Balb/C female mice. According to the results in Table 3, the treated groups showed a significant reduction (p < 0.05) in tumor size compared with the negative control, which registered an increase in tumor size of 88.87%. Noteworthy, the triple combination of cisplatin, WSR extract, and IF recorded the highest percentage in the size reduction (100%) and curable rate (100%). Besides, the combination of WSR extract and IF recorded the lowest percentage of size reduction (60.52%) among the combination treatments, along with a curable rate of 50%. The combination of WSR extract and cisplatin registered a reduction in tumor size of 81.12% with a curable rate of 50%. As observed, the same treatments were applied to EMT6/CPR cells. Tumor size was reduced remarkably (p < 0.05) for all treated groups as opposed to the negative control, which showed an increase in tumor size of 60.02% from the initial tumor size. Interestingly, combination treatments had higher tumor size reduction than single treatments. Regarding triple treatment, it registered a complete reduction in tumor size (100%); therefore, there were no mice with detectable tumors (100%). On the flip side, the WSR extract and cisplatin combination exhibited a higher reduction in tumor size than the WSR extract and IF combination (69.49 and 53.36%, consequently), besides the same curable rate (66.66%).

Generally, single treatment revealed a lower reduction in tumor size than combination treatments. The analysis showed that EMT6/P complied with the positive control (cisplatin) more than the WSR extract and IF as cisplatin reduced the tumor by 74.21% against 50% of mice with no detectable tumor. WSR extract and IF displayed approximately the same reduction in tumor size (51.97 and 52.75%, respectively) and the same curable rate (33.33%). In EMT6/CPR, the cells responded to WSR extract in a way better than the other single treatments by 40.49% lowering in tumor size and 50% curable rate. Fasting recorded a higher reduction in tumor size compared to cisplatin, with values of 37.22 and 18.80%, respectively, along with the same curable rate of 33.33%. Figures 6A,B illustrate the difference between treatments in tumor volume reduction at three timepoints during treatments. The change in tumor size can be ascertained from Figures 6C,D, which show the final average volumes of the dissected tumors.

Effect of Treatments on Mice’s Average Weight

Concerning mice body weight, all treated groups registered weight loss except the WSR extract-treated group (25), and WSR/IF-treated group registered a significant weight gain compared with the IF-treated group, p < 0.001. Additionally, the control group recorded an increase in body weight (8.21%). Despite the effect of WSR extract on weight gain, cisplatin caused a non-significant weight loss compared to the control (8.20%) when administered either alone (~2.29%), along with WSR extract (~5.56%), or with WSR extract and IF (~8.71%; Figure 7).

Effect of the Treatments on Glucose and β-Hydroxybutyrate Levels

The subsequent analysis of glucose levels showed that treatments with IF had the lowest level of glucose either as a single treatment or in combination (p < 0.001). Generally, WSR extract-treated groups had lower glucose levels than the single treatment cisplatin or the control, and when we compared IF alone or along with WSR extract, nevertheless, the reduction was insignificant (Figure 8A). Additionally, we were interested to

### Table 1

| No. | Compound              | Molecular formula | RT (min) | Amount (%) |
|-----|-----------------------|-------------------|----------|------------|
| 1   | Succinic acid         | C4H6O4            | 0.98     | 68.52      |
| 2   | Gallic acid           | C7H6O5            | 1.04     | 7.52       |
| 3   | Protocatechelic aldehyde | C7H6O3        | 2.09     | 0.01       |
| 4   | Chlorogenic acid      | C16H18O9          | 2.88     | 2.81       |
| 5   | Vanillic acid         | C8H8O4            | 3.2      | 0.18       |
| 6   | Caffeic Acid          | C9H8O4            | 3.27     | 0.28       |
| 7   | Anthranillic acid     | C7H7NO2           | 4.07     | 16.87      |
| 8   | Apin                  | C2H2BO14          | 5.11     | 0.01       |
| 9   | Ferulic acid (trans) | C10H10O4          | 5.13     | 0.40       |
| 10  | Rutin                 | C2H8O2            | 5.58     | 0.40       |
| 11  | 3,5-Dimethoxy-4-hydroxy acetonaphone | C10H12O4 | 5.63 | 1.29 |
| 12  | Salicylic acid        | C7H6O3            | 5.78     | 0.01       |
| 13  | Spiraeoside           | C21H20O12         | 5.78     | 0.81       |
| 14  | Kaempferol            | C15H10O6          | 10.13    | 0.07       |
| 15  | Isoharmenin           | C16H12O7          | 10.51    | 0.32       |

Frontiers in Nutrition | www.frontiersin.org 7 July 2022 | Volume 9 | Article 863619
evaluate the comparative profiles between the treatment groups concerning their effect on the level of BHB. As expected, IF and its combination resulted in the highest values of BHB with a significant difference ($p < 0.05$) from the others (Figure 8B).

### Safety Profile

Alanine aminotransferase and AST assays were performed as they are considered markers for liver toxicity. Serum levels of the liver enzymes were measured for all treated groups with WS extract, IF, cisplatin, their combinations, the negative (untreated) control, and tumor nonbearing mice, which did not bear any tumors as a reference for liver function. The current study found that the levels of serum ALT are within the normal range for all treated groups compared with the normal-untreated mice, however, cisplatin-treated group recorded significantly higher ALT value. In turn, the cisplatin group recorded 63.88 IU/L of ALT, which is 1.77 times higher than the normal group, although combination groups that included cisplatin revealed better results with lower values of ALT levels (45.33 and 25.83 IU/L for cisplatin with WSR

---

### Table 2 | IC$_{50}$ Values for the Extract and Cisplatin in Cisplatin-Sensitive (EMT6/P) and Cisplatin-Resistant (EMT6/CPR) Cell Lines Along with the Combination Index, Related Interpretation, and Resistance Fold.

| Cell line | IC$_{50}$ of WSR extract (mg/mL) | IC$_{50}$ of cisplatin (µM) | WSR extract IC$_{50}$ in combination (mg/mL) | Cisplatin IC$_{50}$ in combination (µM) | CI | Interpretation |
|-----------|---------------------------------|-----------------------------|------------------------------------------|-------------------------------------|----|----------------|
| EMT6/P    | 2.9 ± 0.18                      | 20 ± 0.5                    | 0.54 ± 0.011                             | 10                                  | 0.78 | Moderate synergism |
| EMT6/CPR  | 3.8 ± 0.09                      | 54 ± 0.08                   | 0.66 ± 0.05                              | 27                                  | 0.76 | Moderate synergism |
| RF        | 1.31                            | 2.7                         | 1.22                                     | 2.7                                 |     |                |

Data are presented as mean ± SEM ($n = 3$). CI, combination index; RF, resistance fold.
FIGURE 5 | Caspase-3 activity in breast cancer cells after treatment with WSR extract and cisplatin. (A) Treatment of EMT6/P cells with cisplatin (20 µM), WSR extract (2.9 mg/ml), and their combination (10 µM cisplatin with 0.54 mg/ml WSR extract). (B) Treatment of EMT6/C cells with cisplatin (54 µM), WSR extract (3.8 mg/ml), and their combination (27 µM cisplatin with 0.66 mg/ml WSR extract) in EMT6/C cell line. Results are expressed as means ± SEM (n = 3). *P < 0.05, **P < 0.001. (†: treatments groups compared with the control group).

TABLE 3 | Results of WSR extract, intermittent fasting (IF), cisplatin and their combinations concerning tumor size changes, percentage of changes in tumor size, and average tumor weight in EMT6/P and EMT6/CPR cell line.

| Treatment group | Av. initial tumor size (mm$^3$) | Av. final tumor size (mm$^3$) | (%) change in tumor size | (%) mice with no detectable tumor | Av. tumor weight (gm) |
|-----------------|-------------------------------|-------------------------------|--------------------------|---------------------------------|----------------------|
| **EMT6/P**      |                               |                               |                          |                                 |                      |
| Control         | 358.05 ± 35.02                 | 676.24 ± 170.41               | 88.87                    | 0                               | 0.54 ± 0.172        |
| Cisplatin       | 291.80 ± 12.86                 | 75.25 ± 4.77                  | –74.21                   | 50                              | 0.066 ± 0.004       |
| WSR             | 367.13 ± 46.79                 | 176.34 ± 33                   | –51.97                   | 33.33                           | 0.151 ± 0.021       |
| IF              | 381.63 ± 24.84                 | 180.33 ± 19.30                | –52.75                   | 33.33                           | 0.127 ± 0.023       |
| WSR + IF        | 330.25 ± 18.14                 | 130.37 ± 12.87                | –60.52                   | 50                              | 0.105 ± 0.007       |
| WSR + cisplatin | 389.23 ± 21.22                 | 75.50 ± 7.72                  | –81.12                   | 50                              | 0.069 ± 0.001       |
| WSR + IF + cisplatin | 351.42 ± 37.10             | 0.0                            | –100                     | 100                             | 0.0                 |
| **EMT6/CPR**    |                               |                               |                          |                                 |                      |
| Control         | 215.38 ± 15.57                 | 344.65 ± 64.71                | 60.02                    | 33.33                           | 0.275 ± 0.04        |
| Cisplatin       | 200.54 ± 34.27                 | 162.84 ± 17.19                | –18.80                   | 33.33                           | 0.132 ± 0.026       |
| WSR             | 248.48 ± 26.55                 | 147.88 ± 4.96                 | –40.49                   | 50                              | 0.135 ± 0.008       |
| IF              | 210.35 ± 23.37                 | 132.06 ± 3.90                 | –37.22                   | 33.33                           | 0.085 ± 0.009       |
| WSR + IF        | 246.99 ± 16.34                 | 115.20 ± 3.30                 | –53.36                   | 66.66                           | 0.08 ± 0.001        |
| WSR + cisplatin | 247.23 ± 21.63                 | 75.42 ± 3.21                  | –69.49                   | 66.66                           | 0.05 ± 0.001        |
| WSR + cisplatin + IF | 212.85 ± 22.57             | 0.0                            | –100                     | 100                             | 0.0                 |

Av., average; mm³, cubic millimeter; gm, gram. Data are expressed as means ± SEM (N = 6).

Additionally, the effect of WSR extract, IF, and their combination on ALT levels were 36.66, 25.12, and 26.94 IU/L, respectively (Figure 9A). However, serum AST levels were normal for all treatment groups compared with the tumor nonbearing mice as they recorded an insignificant difference with $p > 0.05$. The cisplatin-treated group achieved a higher value than the tumor nonbearing mice (74.04 and 63.32 IU/L, respectively). However, this difference was insignificant ($p = 0.195$). Moreover, combination treatments, including cisplatin, registered lower
FIGURE 6 | Effect of treatments on tumor size in vivo. (A) A plot of change in average tumor size (mm$^3$) vs. time (days) of treatment in the EMT6/P cell line. (B) A plot of change in average tumor size (mm$^3$) vs. time (days) of treatment in EMT6/CPR cell line. (C) Tumor sizes in EMT6/P cells after dissection on day 10 in all groups compared to each other. (D) Tumor sizes of EMT6/CPR cells after dissection at day 10 in all groups compared to each other. (1 = negative control; 2 = cisplatin; 3 = WSR; 4 = IF; 5 = WSR + IF; 6 = WSR + cisplatin; 7 = WSR + IF + cisplatin). Results are expressed as means ± SEM ($n = 6$). $^*P < 0.05$, $^{**}P = 0.001$, $^{***}P < 0.001$. (*: treatment groups compared with the control group).

FIGURE 7 | Mice average weight (gm) on days 1 and 10 in all groups compared with each other. (%): percentage of change in body weight. Results are expressed as means ± SEM ($n = 6$).
values of AST (57.77 and 50.83 IU/L for cisplatin with WSR extract and the triple combination with IF, respectively; Figure 9B).

In the case of serum creatinine, normal levels of creatinine were observed between tumor nonbearing mice and the other mice groups, which were treated with the above-mentioned treatments. However, the single treatment of cisplatin increased creatinine levels significantly (1.2 mg/dl with a \( p \) value of 0.001). Note that combined treatment of cisplatin with either WSR extract or WSR extract and IF showed lower creatinine levels than cisplatin alone, with values of 0.81 and 0.79 mg/dl, respectively (Figure 9C).

**DISCUSSION**

Diverse obstacles hinder the successful treatment of breast cancer due to toxicity to normal cells, the narrow therapeutic index of chemotherapy, and MDR. The latter is a major obstacle because MDR has accounted for the failure of treatments and subsequently death (26). The combination of chemotherapy with natural products is widely used these days to overcome MDR (27). As another option, IF can reduce tumor incidence, potentiate the effectiveness of chemotherapy, and improve the response to chemotherapy (28). In this research, water extract of WSR and IF was examined compared with cisplatin in vitro using EMT6/P and EMT6/CPR breast cancer cell lines and in vivo using female Balb/C mice inoculated with EMT6/P and EMT6/CPR breast cancer cell lines. In vitro and in vivo tests showed promising results. It is worth mentioning that the WSR extract, IF combination, and triple combination have not been tested before.

In vitro, our results based on the viability assay indicated that WSR extract prevented EMT6/P and EMT6/CPR cell line viability in a concentration-dependent pattern. The present results agree with previous studies. Prasad et al. (29) observed a dose-dependent anti-breast cancer activity for the crude water extract of WSR on MCF-7 cell lines (29). This antiproliferative effect of the WSR extract is related to its content of anticancer components (Table 1). Based on the previous finding, succinic acid (68.52%) revealed an apoptotic effect on acute lymphoblastic leukemia (T-ALL cell line) and increased caspase-3 activity in human leukemic lymphoblasts (CCRF-CEM cell line) in vitro (30). Additionally, anthranilic acid (16.87%) has been widely used with its derivatives to fight cancer and it has an antiproliferative effect (31). Furthermore, the phenolic compounds, gallic acid (7.52%) can reduce viability and promote apoptosis (32) by upregulation of Fas and FasL and induction of p53 and caspase-3 (33). The latter is considered a key enzyme in the execution of apoptosis (5). Considering that WSR extract caused a dramatic increase in caspase-3 levels in both EMT6/P and EMT6/CPR cell lines, and that potentiates the apoptotic effect and reduce viability (Figures 5A,B). These outcomes were matched with a previous study where the caspase-3 activity was enhanced upon the use of WSR extract on MDA-MB231 (34).

Cisplatin was used as a positive control, along with the WSR extract. WSR extract with cisplatin showed a moderate synergism in both cell lines and reduced the used dose of cisplatin influentially, in addition to their ability to reduce the resistance fold of cisplatin (Table 2). Thus, it was concluded that WSR extract alongside cisplatin resulted in greater synergism than any other combination tested alone. Consistent with previous studies, withaferin A synergized the effect of paclitaxel on both drug-sensitive and drug-resistant NSCLC cells in vitro (35). Also, the antiapoptotic effect of this combination enhanced the level of caspase-3 effectively compared with the control, WSR extract-treated cells, and cisplatin-treated cells in both cell lines. As noted, WSR extracts remarkably potentiated the cisplatin response in the resistant cell line (Figures 5A,B), which means that WSR extract sensitized the resistant cell line to cisplatin at lower doses. Previously, Cohen et al. (36) showed that withaferin A along with sorafenib raised caspase-3 levels efficiently in papillary and anaplastic cancers (36).
Different treatments were tested in vitro in this research. In agreement with in vitro data, WSR extract reduced tumor size in EMT6/P and EMT6/CPR in vivo to 51.97 and 40.49%, respectively (Table 3). These findings follow previous studies where water extract of WS reduced tumor size in mice bearing cervical (HeLa) and colorectal (HT-29) cell-derived tumors (37). Another previous study observed that withaferin A, a component in WSR, showed in vivo antitumor effect by reducing the tumor size in both EMT6/P and EMT6/CPR tumor-bearing mice by 52.75 and 37.22%, respectively (Table 3). It has been reported that IF reduced tumor size in a colon cancer xenograft mice model (CT26 cells) (39). Depending on that, the proposed antitumor effect of IF is due to reversing the Warburg effect and increasing BHB. Both have approved antitumor activity as mentioned before. Moreover, serum glucose level is an indicator for the Warburg effect (16), which was tested in this study. Based on the obtained results, cancer-induced mice that were treated with IF displayed a considerable serum glucose reduction compared with the control group (Figure 8A), which means that the Warburg effect was reversed and this was also proved before (40). The same groups had a higher level of BHB, which is considered an anticancer molecule (41) (Figure 8B).

Different combinations were explored in vivo in this research. First, combination treatment of WSR extract and cisplatin showed more size reduction of tumor (81.12 and 69.49% in mice bearing EMT6/P and EMT6/CPR cell lines, respectively; Table 3). These observations provided the basis that cisplatin and its combination with WSR extract resulted in greater efficacy and potency than the use of the drug alone in both cell lines. Interestingly, WSR extract sensitized the resistant cell line to cisplatin, remarkably.

Alternatively, a combination treatment of WSR extract and IF resulted in more tumor size reduction (60.52%) compared with a single treatment of WSR extract (51.97%) and IF (52.75%) in EMT6/P cells. Furthermore, combination treatment of WSR extract and IF resulted in more tumor size reduction (53.36%) compared with single treatment WSR extract (40.49%) and IF (37.22%) in EMT6/CPR cells. This combination has not been tested before; however, IF showed a synergistic effect with ascorbic acid vs. Kirsten rat sarcoma virus, a gene that makes a protein that is involved in cell signaling pathways that control cell growth, cell maturation, and cell death (KRAS) mutated cancers.
FIGURE 10 | The proposed mechanisms for WSR extract and IF combination and how they can evade cancer and sensitize resistant cells to cisplatin, when added, based on the results obtained from this study and former studies. SA, succinic acid; GA, gallic acid; ROS, reactive oxygen species; TCA, tricarboxylic acid cycle.

(42). Others observed that the combination of WS and Maitake (Grifola frondosa) extract had a synergistic effect on immunity (43). Moreover, WSR extract induced oxidative stress, which could potentiate the effect of IF by reversing the Warburg effect (44). WSR extract countered the effect of IF on mice’s weight significantly (Figure 7).

The mechanistic analysis provided in the literature demonstrates that WS can sensitize cancerous cells to chemotherapy through the apoptotic pathway, which is considered a predominant pathway for cisplatin-induced cell death. WS activates tumor suppressor p53, a fundamental element for inducting cisplatin-induced apoptosis and overcoming resistance (45). Primarily, A can block the autophagy flux in breast cancer cell lines MCF7 and MDA-MB-231, which is considered another method to reverse chemoresistance (46).

It was imperative to examine the last combination, which included IF, WSR extract, and cisplatin. Further reduction in tumor size was detected by adding IF to the extract and cisplatin leading to complete vanishment of the tumor in the sensitive and resistant cell lines. That supported the synergistic effect of IF in both cell lines. Moreover, IF succeeded to sensitize the resistant cell lines to cisplatin and that was confirmed by the complete reduction of the tumor. Interestingly, this combination has not been evaluated in the literature (Figure 6; Table 3). Nevertheless, IF can reverse MDR by several pathways as revealed in the literature. The first way is by increasing p53, which is substantial for sensitization (47). By the same token, IF suppresses IGF-1 and IGF-1 receptors and that increases sensitivity to chemotherapy (48). Figure 10 illustrates the proposed mechanisms for WSR extract and IF combination and how they can evade cancer and can sensitize resistant cells to cisplatin, when added, based on the results obtained from this study and former studies.

The safety profile of anticancer agents is crucial to evaluating their toxicity. Liver enzymes (ALT and AST) and creatinine were used as indicators of liver and kidney functions, respectively. Results demonstrated that all treated groups had a normal level of ALT, except the cisplatin-treated group. As mentioned previously, cisplatin can induce hepatotoxicity. Combination treatments showed lower ALT levels than single treatment with cisplatin (Figure 9A). On top of that, AST levels were normal in the treated groups without exception. Nevertheless, combination treatments revealed lower AST levels than cisplatin alone (Figure 9B). In the literature, the extract of WSR showed hepatoprotective and antioxidant effects on radiation-induced hepatotoxicity (49). In contrast, creatine levels were normal in the treatment groups, excluding the cisplatin-treated group. The explanation for this finding is that cisplatin induces nephrotoxicity, which is one of the most serious obstacles that hinder cisplatin use (50). Despite that, combination treatment relieved the nephrotoxicity of cisplatin (Figure 9C). Formerly, water extract caused a remarkable elevation in the antioxidant activities of glutathione and superoxide dismutase to conserve renal tissue damage from gentamicin (51).

CONCLUSION

Based on the data presented here, we concluded that the combination of WSR extract and cisplatin has a synergistic anticancer effect on both the parent and the resistant cell lines in vitro and in vivo, better than cisplatin alone through apoptosis.
induction and caspase-3 activation. On the other hand, the combination of IF with WSR extract has a superior ability to cause a reduction in tumor size. The activity of this combination was enhanced in the presence of cisplatin and caused complete tumor regression. These combinations are safer for the liver and kidney than the conventional therapy cisplatin. Such novel findings are worth the opportunity of expanding the range of research to establish better treatment for breast cancer in the future. Further studies are needed to evaluate the expression levels of antiapoptotic genes including Bcl2, BAX, and caspase 8 and to study morphological changes in cells after treatment.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by Research and ETHICS STATEMENT directed to the corresponding author.

AUTHOR CONTRIBUTIONS

SJ: experimental work, data collection, data analysis, and wrote the original draft. WT: conceptualization, the direction of the work, supervision, data analyses, wrote revision, and editing. Both authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We also acknowledge with gratitude MSc. Asmaa Mahmoud and Mr. Salem Al Shawabkeh (Department of Clinical Pharmacy and Therapeutics, Applied Science Private University) for their technical assistance.

REFERENCES

1. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk factors and prevention of breast cancer. *Int J Biol Sci.* (2017) 13:1387–97. doi: 10.7150/ijbs.21635

2. Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. *Dalton Trans.* (2018) 47:6645–53. doi: 10.1039/c8dt00838h

3. Ji X, Lu Y, Tian H, Meng X, Wei M, Cho WC. Chemoresistance mechanisms of breast cancer and their countermeasures. *Biomed Pharmacother.* (2019) 114:108800. doi: 10.1016/j.biopharm.2019.108800

4. Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linç A, Machuqueiro M, et al. The multi-factorial nature of clinical multidrug resistance in cancer. *Drug Resist Update.* (2019) 46:100645. doi: 10.1016/j.drup.2019.100645

5. Abotaleb M, Samuel S, Varghese E, Varghese S, Kubatka P, Liskova A, et al. Flavonoids in Cancer and Apoptosis. *Cancers.* (2018) 11:28. doi: 10.3390/cancers11010028

6. Pfeffer C, Singh A. Apoptotic: a target for anticancer therapy. *JMS.* (2018) 19:1448. doi: 10.3390/jms19020448

7. Campbell TC. Nutrition and cancer: an historical perspective – the past, present, and future of nutrition and cancer. Part 2. Misunderstanding and ignoring nutrition. *Nutr Cancer.* (2017) 69:962–8. doi: 10.1080/01635381.2017.1339094

8. Afewerky HK, Ayodeji AE, Tiamiyu BB, Orege JI, Oyejobi AO, et al. Critical review of the *Withania somnifera* (L.) Dunal: A modern perspective of an ancient Rasayana from Africa. *Bull Natl Res Cent.* (2021) 45:176. doi: 10.1186/s42269-021-00635-6

9. Kim S, Yu JS, Lee JY, Choi SU, Lee J, Kim KH. Cytotoxic withanolides from the roots of Indian Ginseng (*Withania somnifera*). *J Nat Prod.* (2019) 82:765–73. doi: 10.1021/acs.jnatprod.8b00665

10. O’Flanagan CH, Smith LA, McDonell SB, Hursting SD. When less may be more: calorie restriction and response to cancer therapy. *BMC Med.* (2017) 15:106. doi: 10.1186/s12916-017-0873-x

11. Mukherjee PK, Banerjee S, Biswas S, Das B, Kar A, Katiyar CK. *Withania somnifera* (L.) Dunal – Modern perspectives of an ancient Rasayana from Ayurveda. *J Ethnopharmacol.* (2021) 264:113157. doi: 10.1016/j.jep.2020.113157

12. Thorat SA, Poojari P, Kaniyassery A, Kiran KR, Satyamoorthy K, Mahato KK, et al. Red laser-mediated alterations in seed germination, growth, pigments and withanolide content of Ashwagandha [*Withania somnifera* (L.) Dunal]. *J Photochem Photobiol B Biol.* (2021) 216:112144. doi: 10.1016/j.jphotobiol.2021.112144

13. Halder B, Thakur SS. *Withania somnifera* Has Potential to Treat Cancer. In: Kaul SC, Wadhwa R editors. *Science of Ashwagandha: Preventive and Therapeutic Potentials*. Cham: Springer International Publishing (2017). p. 213–26. doi: 10.1007/978-3-319-59192-6_10

14. Senthilnathan P, Padmavathi R, Magesh V, Sakhthisekaran D. Chemotherapeutic efficacy of paclitaxel in combination with *Withania somnifera* on benzo (a) pyrene-induced experimental lung cancer. *Cancer Sci.* (2006) 97:658–64. doi: 10.1111/j.1349-7006.2006.00224.x

15. Riccò M, Garbarino S, Bragazzi NL. Migrant workers from the eastern-mediterranean region and occupational injuries: a retrospective database-based analysis from North-Eastern Italy. *Int J Environ Res Public Health.* (2019) 16:673. doi: 10.3390/ijerph16040673

16. Turbitt WJ, Demark-Wahnefried W, Peterson CM, Norian LA. Targeting glucose metabolism to enhance immunotherapy: emerging evidence on intermittent fasting and calorie restriction mimetics. *Front Immunol.* (2019) 10:1402. doi: 10.3389/fimmu.2019.01402

17. Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. *Ageing Res Rev.* (2017) 39:46–58. doi: 10.1016/j.arr.2016.10.005

18. Icard P, Shulman SR, Farhat D, Steyaert J-M, Alizano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells. *Drug Resist Updat.* (2018) 38:1–11. doi: 10.1016/j.drup.2018.03.001

19. Kumar S, Harris RJ, Seal CJ, Okello EJ. An aqueous extract of *Withania somnifera* root inhibits amyloid β fibril formation in vitro. *Phytother Res.* (2012) 26:113–7. doi: 10.1002/ptr.3512

20. ElNaker NA, Daou M, Ochienskühn MA, Amin SA, Yousef AF, Yousef LF. A metabolomics approach to evaluate the effect of pyrolithium versus oven drying on the chemical composition of plant extracts. *Sci Rep.* (2021) 11:22679. doi: 10.1038/s41598-021-02158-6

21. Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M. Enhancement of docetaxel anticancer activity by a novel indolylmethane compound in
human non-small cell lung cancer. Clin Cancer Res. (2009) 15:543–52. doi: 10.1185/1078-0432.CCR-08-1558
22. Wang X-B, Wang S-S, Zhang Q-F, Liu M, Li H-L, Liu Y, et al. Inhibition of tetramethylpyrazine on P-gp, MR2P, MR3P and MR3P in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep. (2010) 23:211–5. doi: 10.3892/or_00000625
23. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, et al. Loss of BRCAl function increases the antioxidant activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther. (2009) 8:648–53. doi: 10.4161/cbt.AU_16.37
24. Niu C, Zong Z, Zhang X, Wu R, Li N, Wang H, et al. Synthesis, structures and biological activity of novel complexes with trifluorinated anthranilic acid derivatives. J Mol Struct. (2019) 1194:42–7. doi: 10.1016/j.molstruc.2019.05.062
25. Varela-Rodríguez L, Sánchez-Ramírez B, Hernández-Ramírez VL, Varela-Rodríguez H, Castellanos-Mijangos RD, González-Horta C, et al. Effect of Gallic acid and Myricitrin on ovarian cancer models: a possible alternative antitumoral treatment. BMC Complement Med Ther. (2020) 20:110. doi: 10.1186/s12906-020-02900-z
26. Liu C, Zong Z, Zhang X, Wu R, Li N, Wang H, et al. Synthesis, structures and biological activity of novel complexes with trifluorinated anthranilic acid derivatives. J Mol Struct. (2019) 1194:42–7. doi: 10.1016/j.molstruc.2019.05.062
27. Prasad KS, Prasad SK, Veerapur R, Lamraoui G, Prasad A, Prasad MNN, et al. Antitumor potential of green synthesized ZnONPs using root extract of Withania somnifera against human breast cancer cell line. Separations. (2021) 8:8. doi: 10.3390/separations8010008
28. Erstrup B, Ippol B, Kalm K. In vitro inhibitory effect of succinic acid on T-Cell acute lymphoblastic leukemia cell lines. Arch Med Res. (2021) 52:270–6. doi: 10.1016/j.arcmed.2020.10.022
29. Niu C, Zong Z, Zhang X, Wu R, Li N, Wang H, et al. Synthesis, structures and biological activity of novel complexes with trifluorinated anthranilic acid derivatives. J Mol Struct. (2019) 1194:42–7. doi: 10.1016/j.molstruc.2019.05.062
30. Varela-Rodríguez L, Sánchez-Ramírez B, Hernández-Ramírez VL, Varela-Rodríguez H, Castellanos-Mijangos RD, González-Horta C, et al. Effect of Gallic acid and Myricitrin on ovarian cancer models: a possible alternative antitumoral treatment. BMC Complement Med Ther. (2020) 20:110. doi: 10.1186/s12906-020-02900-z
31. Tsai C-L, Chiu Y-M, Ho T-Y, Hsieh C-T, Shieh D-C, Lee Y-J, et al. Gallic acid induces apoptosis in human gastric adenocarcinoma cells. Anticancer Res. (2018) 38:2057–67. doi: 10.21873/ anticancer.12445
32. Dar PA, Mir SA, Bhat JA, Hamid A, Singh LR, Malik F, et al. An anticancer protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells. Int J Biol Macromol. (2019) 135:77–87. doi: 10.1016/j.jbiomac.2019.05.120
33. Kyakulaga AH, Aqil F, Munagala R, Gupta RC. Synergistic combinations of Kyakulaga AH, Aqil F, Munagala R, Gupta RC. Synergistic combinations of succinic acid and folic acid receptor-mediated targeting enhances the cytotoxicity, efficacy, and selectivity of Withania somnifera leaf extract: in vitro and in vivo evidence. Front Oncol. (2019) 9:602. doi: 10.3389/fonc.2019.00602
34. Shah HS, Usman F, Ashfaq-Khan M, Khalil R, Ul-Haq Z, Mushtaq A, et al. Preparation and characterization of anticancer niosomal withaferin-A formulation for improved delivery to cancer cells: in vitro, in vivo, and in silico evaluation. J Drug Deliv Sci Technol. (2020) 59:101863. doi: 10.1016/j.jddst.2020.101863
35. Sun P, Wang H, He Z, Chen X, Wu Q, Chen W, et al. Fasting inhibits colorectal cancer growth by reducing M2 polarization of tumor-associated macrophages. Oncotarget. (2017) 8:74649–60. doi: 10.18632/oncotarget.20301
36. Weng M, Chen W, Chen X, Lu H, Sun Z, Yu Q, et al. Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Erbin-mediated AKT/mTOR/HTF1α pathway suppression. Nat Commun. (2020) 11:1869. doi: 10.1038/s41467-020-15795-8
37. Korde JM, Kandasubramanian B. Microbiologically extracted poly (hydroxyalkanoates) and its amalgams as therapeutic nano-carriers in anti-tumor therapies. Mater Sci Eng C. (2020) 111:110799. doi: 10.1016/j.msec.2020.110799
38. Di Tano M, Raucci F, Vernieri C, Caffa I, Buono R, Fanti M, et al. Synergistic effect of fasting-mimicking diet and vitamin C against KRAS mutated cancers. Nat Commun. (2020) 11:2332. doi: 10.1038/s41467-020-16243-3
39. Vetrivcka V, Vetvickova J. Immune enhancing effects of WB365, a novel combination of Ashwagandha (Withania somnifera) and Maitake (Grifola frondosa) extracts. North Am J Med Sci. (2011) 3:320–4. doi: 10.4297/najms.2011.3320
40. Henley AB, Yang L, Chuang K-L, Sahuri-Arisoylu M, Wu L-H, Bligh SWA, et al. Withania somnifera root extract enhances chemotherapy through ‘Priming’. PLoS One. (2017) 12:e0170917. doi: 10.1371/journal.pone.0170917
41. Sun C, Zhu Y, Li X, Wang X, Tang L, Su Z, et al. Scutellaris increases cisplatin-induced apoptosis and autophagy to overcome cisplatin resistance in non-small cell lung cancer via ERK/p53 and c-met/AKT signaling pathways. Front Pharmacol. (2018) 9:92. doi: 10.3389/fphar.2018.00092
42. Muniraj N, Siddharth S, Nagalingam A, Walker A, Woo J, Györfy B, et al. Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells. Carcinogenesis. (2019). [Online ahead of print]. doi: 10.1093/carcin/bgz015
43. Krstic J, Reinisch I, Schindlmairer K, Gallhuber M, Berger N, Kupper N, et al. Fasting reverses drug-resistance in hepatocellular carcinoma through p53-dependent metabolic synergism. Cancer Biol. [Preprint]. (2021). doi: 10.1101/2021.02.10.43054
44. Zhao X, Yang J, Huang R, Guo M, Zhou Y, Xu L. The role and its mechanism of intermittent fasting in tumors: friend or foe. Cancer Biol Med. (2021) 18:63–73. doi: 10.20892/issn.2095-3941.2020.0250
45. Khalil HM, Elwiwa HA, El-Shiekh RA, Al-Mokaddem AK, Hassan M, Tawfek AM, et al. Ashwagandha (Withania somnifera) root extract attenuates hepatic and cognitive deficits in thioacetamide-induced rat model of hepatic encephalopathy via induction of Nrf2/HO-1 and mitigation of NF-kB/MAPK signaling pathways. J Ethnopharmacol. (2021) 277:114141. doi: 10.1016/j.jep.2021.114141
46. Casanova AG, Hernández-Sánchez MT, López-Hernández FJ, Martinez-Salgado C, Prieto M, Vicente-Vicente L, et al. Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity. Eur J Clin Pharmacol. (2020) 76:23–33. doi: 10.1007/s00228-019-02771-5
47. Govindappa PK, Gattam V, Tripathi SM, Sahni YP, Raghavendra HLS. Effect of Withania somnifera on gentamicin induced renal lesions in rats. Rev Bras Farmacogn. (2019) 29:234–40. doi: 10.1590/1806.805
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Copyright © 2022 Jawarneh and Talib. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided that the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.